ASPIRE

The ASPIRE trial investigates if adding ultrasound-guided corticosteroid injections to standard care improves pain and function in chronic Achilles tendinopathy.

Research Subject Matter and Aim
Midportion Achilles tendinopathy is a common injury affecting both active and sedentary populations. Patients experience local pain, stiffness and disability. Frequently for months, or even years, despite receiving standard exercise therapy and education. This makes it a challenging condition for both patients and healthcare providers. Our research aims to improve the treatment of chronic midportion Achilles tendinopathy, by investigating whether corticosteroid injections can provide a safe and effective second-line treatment for those who do not respond to standard care.

Execution of the Project
We are conducting a randomized, double-blind, placebo-controlled, multicenter trial in which we will evaluate the effects of ultrasound-guided peritendinous corticosteroid injections combined with standard care compared to a placebo group, over a long-term follow-up period of 10 years. The primary outcomes include changes in symptoms and disability and the incidence of tendon ruptures.

Impact on Patient Care
The results of this trial could significantly influence clinical practice by providing evidence-based guidance on the added value and potential risks of corticosteroid injections for patients with chronic midportion Achilles tendinopathy. This clarity will help determine whether these injections offer a beneficial second-line treatment option. Moreover, the integration of these findings into (inter)national guidelines may contribute to more standardized care, ensuring equal treatment approaches across different healthcare providers.